Antibacterial Agents TRIZ Cases

A segmented PEVB backbone-helper plasmid system enables non-pathogenic vaccine antigen delivery to pig respiratory and digestive tracts.

Lipid nanoparticles combine ionizable amino lipids with phospholipids and PEG lipids to balance nucleic acid stability and cell entry.

A composite formula combines herbal extracts, hydrosols, borneol, chelated platinum ions, and antibacterial agents for sustained protection.

Magnetic sorting, lentiviral transduction, and immune-factor induction enhance MSC immunosuppression for sepsis and arthritis.

PmSLP protein vaccines broaden protection against Pasteurella strains and reduce reliance on antimicrobials.

Timed pegbovigrastim administration strengthens natural defenses against mastitis without antibiotics during dry-off.

This case replaces strain-specific capsule targeting with recombinant PmSLP proteins to broaden protection and reduce antimicrobial use.

This case uses stored autologous fecal samples in oral capsules to avoid donor screening and hospital procedures while treating dysbiosis.

This case combines EBV B-cell antigens with antibody fragments to trigger phagocytosis, ADCC, and complement activation without Fc regions.

Homogenized, filtered, cryopreserved donor samples support standardized delivery and bacterial viability in C. difficile bacteriotherapy.

This case uses sulfonyl fluoride amino acids and SuFEx chemistry to improve selectivity, efficiency, and target conjugation.

This case uses lytic bacteriophages to remove IBD-associated Klebsiella, lowering load and inflammation while preserving gut microbiota.

This case uses SEQ ID NO: 1 or 2 depolymerase variants to degrade K47 Klebsiella EPS and improve antibiotic access.

Hydrocarbon-stapled peptides improve stability, bacterial uptake, and antimicrobial potency while limiting human-cell lysis.

A purified multi-strain consortium addresses relapse and donor risks by restoring gut microbiome balance without fecal transplantation.

Hydrogenation, carboxylation, benzylation, and amide formation improve TXA709 synthesis yields for commercial-scale preparation.

This case uses non-toxic Cholix386 domains to mediate transcytosis of siRNA and other cargo across intestinal epithelium.

Olv1 and Olv2 defensin proteins can be produced in host cells to address resistant biofilms with broad-spectrum antimicrobial activity.

This case isolates shared iron-regulated Pasteurella proteins to broaden vaccine protection beyond represented serotypes.

This case combines repeated MOMP fragments with T-cell antigens to improve neutralizing responses across Chlamydia serovars.

This case uses OIv1 and Olv2 defensin proteins, optimized in E. coli, to address resistant pathogens and Candida.

Hesperidin and citral hinder ACE2 attachment while sodium alginate forms a temporary mucosal film to reduce SARS-CoV-2 transmission.

This case combines mutant fHbp variants in fusion proteins to address limited MenB coverage and improve bactericidal antibody responses.

This case uses Lactobacillus and Bifidobacterium strains to suppress intestinal colonization and proliferation of drug-resistant bacteria.

Lysin A, Lysin B, isoamylase, and α-amylase are formulated in lipid nanoparticles or micelles to disrupt intracellular mycobacteria.

Balances nitric oxide production to support antiviral immunity and limit oxidative stress.

This case combines recombinant RTX toxin expression with an LPS-free vaccine formulation to protect pigs against A. pleuropneumoniae.

A two-polysaccharide mucoadhesive carrier retains topical insulin at wound tissue to address impaired diabetic-ulcer repair.

This case uses Formula-based small molecules to inhibit fascin, addressing migration and invasion that drive metastatic cancer.

Structural modification adds a thiazole-pyridine benzyl quaternary ammonium side chain for antibacterial activity and improved solubility.

This case uses oral probiotic yeast to secrete toxin-binding antibodies, addressing CDI recurrence without disrupting gut microflora.

Bacillus and Pediococcus strains help reduce canine endotoxemia by supporting intestinal barriers and gut microbiota.

This case uses peripheral ACC1/ACC2 inhibition to reduce fat accumulation and improve insulin sensitivity in NASH.

This case uses phosphorylated PEG compounds and plasminogen inhibitors to suppress bacterial virulence and collagen degradation after colon surgery.

This vaccine composition combines fHBP with serogroup A, C, W, and Y saccharides to strengthen coverage and simplify schedules.

Temporal promoter repression reduces host-cell strain during bacteriophage production while enabling high-level protein expression in target bacteria.

Poloxamer F127 and xanthan gum form a controlled-release gel for one-dose treatment, achieving 87% clinical and 78% Nugent cure.

Surface alloying controls antibacterial metal diffusion while preserving stainless steel properties.

This case uses attenuated Neospora caninum strains to trigger IFNγ and IgG responses, reducing tumor volume and limiting growth.

Low solubility limits oral drug exposure; a 1:1 tizoxanide choline salt improves bioavailability and supports therapeutic concentrations.

This case delivers free and liposomal aminoglycoside to the lungs by nebulizer, addressing limited efficacy and adverse events.

This case combines 8-hydroxyquinoline-7-carboxylic acid with antibacterials to inhibit MBLs and address toxicity concerns.

Platelet lysate EVs simplify accessible production for regenerative medicine.

Helper lipids let TLR agonists adsorb to alum as stable nanosuspensions, supporting both antibody and cellular immune responses.

This bifunctional compound targets RNA polymerase while delivering antimetabolite activity against rifampicin-resistant strains.

This case combines anti-Psl and anti-PcrV binding in one therapy to reduce Pseudomonas burden and improve survival.

IL-1 inhibitors, MMP inhibitors, and NIpD proteins aim to limit tissue damage while supporting bacterial clearance.

This composition holds intragastric pH at 5 or more, improving amoxicillin and clarithromycin stability against resistant H. pylori.

At pH 8 or higher, benzyl alcohol works with the active ingredient to improve bacterial and fungal preservation in multiple-use vials.

This case uses PTD-MYC-treated immune cells or fusion protein administration to reduce exhausted T cells and strengthen immune responses.